Iambic Therapeutics
Founded Year
2019Stage
Series B - II | AliveTotal Raised
$206.23MLast Raised
$50M | 10 mos agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+8 points in the past 30 days
About Iambic Therapeutics
Iambic Therapeutics focuses on drug discovery using an AI (artificial intelligence)-driven platform within the pharmaceutical industry. The company specializes in designing optimized medicines by using physics-based AI algorithms to explore chemical space and develop novel mechanisms of action. It primarily serves the healthcare sector by targeting unmet patient needs with its pipeline of therapeutic programs. Iambic Therapeutics was formerly known as Entos. It was founded in 2019 and is based in San Diego, California.
Loading...
Loading...
Research containing Iambic Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Iambic Therapeutics in 4 CB Insights research briefs, most recently on Dec 11, 2024.
Dec 3, 2024 report
Digital Health 50: The most promising digital health startups of 2024
Jul 2, 2024 team_blog
How to buy AI: Assessing AI startups’ potential
Expert Collections containing Iambic Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Iambic Therapeutics is included in 6 Expert Collections, including Digital Health.
Digital Health
11,329 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AI 100 (2024)
100 items
Artificial Intelligence
7,222 items
Digital Health 50
50 items
AI in drug discovery
504 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Iambic Therapeutics Patents
Iambic Therapeutics has filed 7 patents.
The 3 most popular patent topics include:
- energy recovery
- ventilation
- air pollution control systems
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/1/2023 | 11/19/2024 | Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Clusters of differentiation | Grant |
Application Date | 12/1/2023 |
|---|---|
Grant Date | 11/19/2024 |
Title | |
Related Topics | Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Clusters of differentiation |
Status | Grant |
Latest Iambic Therapeutics News
Jan 7, 2025
John Finn named CSO of Basecamp Plus: Iambic hires Michael Secora and updates from Septerna, Beigene, Perspective, Halia and more By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst January 7, 2025 12:35 AM UTC Basecamp Research Ltd. hired John Finn as CSO and Konstantinos Andrikopoulos as SVP for intellectual property, and announced the opening of a lab and office space in Boston, Mass., expanding its footprint from its home base in the U.K. Finn and Andrikopoulos join Basecamp from Tome Biosciences Inc., where they were the same roles. Basecamp, which is developing programmable genetic medicines, raised a Singular-led $60 million series B round in October to scale the dataset for its AI-based biological design platform. AI-based drug discovery company Iambic Therapeutics Inc. hired Michael Secora as chief corporate development officer and CFO. Secora was CFO and executive leader of value translation at Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). ... BCIQ Company Profiles
Iambic Therapeutics Frequently Asked Questions (FAQ)
When was Iambic Therapeutics founded?
Iambic Therapeutics was founded in 2019.
Where is Iambic Therapeutics's headquarters?
Iambic Therapeutics's headquarters is located at 5627 Oberlin Drive, San Diego.
What is Iambic Therapeutics's latest funding round?
Iambic Therapeutics's latest funding round is Series B - II.
How much did Iambic Therapeutics raise?
Iambic Therapeutics raised a total of $206.23M.
Who are the investors of Iambic Therapeutics?
Investors of Iambic Therapeutics include Coatue, Illumina Ventures, Abingworth, Exor Ventures, Qatar Investment Authority and 15 more.
Who are Iambic Therapeutics's competitors?
Competitors of Iambic Therapeutics include Algorithmic Biologics.
Loading...
Compare Iambic Therapeutics to Competitors
Algorithmic Biologics focuses on molecular diagnostics and discovery through technology in the biotech sector. Their main offerings include a software platform with molecular testing workflows to improve efficiency and accuracy, leveraging AI and molecular computing research. The company primarily serves the healthcare industry, particularly in the areas of genomics research and clinical diagnostics. It was founded in 2021 and is based in Bangaluru, India.
10X Genomics (NASDAQ: TXG) specializes in biotechnology and provides tools for analyzing biological systems. The company offers platforms for single cell analysis, spatial gene expression, and in situ gene mapping to facilitate research in various fields of biology. These technologies enable researchers to dissect cellular complexities and contribute to advancements in areas such as oncology, immunology, and neuroscience. 10X Genomics was formerly known as Avente Biosystems. It was founded in 2012 and is based in Pleasanton, California.
Loading...